Original data (with adjusted standard errors for multi-arm studies):

              treat1       treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
10           placebo     zolpidem  0.1640 0.1079     0.1079     0.2349     2         
12       eszopiclone      placebo -0.6593 0.4718     0.4718     0.5158     2         
22          BZD-long      placebo  0.2789 0.3287     0.3287     0.3894     2         
45           placebo   suvorexant  0.2858 0.0958     0.0958     0.2296     2         
46           placebo   suvorexant  0.2180 0.1061     0.1061     0.2341     2         
47           placebo     zolpidem  0.3732 0.4407     0.4407     0.4876     2         
51          BZD-long      placebo -0.0685 0.2458     0.2843     0.3823     3        *
51         BZD-short      placebo  0.0840 0.2829     0.3979     0.4626     3        *
51          BZD-long    BZD-short -0.1525 0.2460     0.2847     0.3826     3        *
52          BZD-long    zopiclone  0.2909 0.6358     0.6358     0.6692     2         
54  BZD-intermediate     BZD-long  1.7699 0.6811     0.6811     0.7123     2         
55          BZD-long    BZD-short -2.3038 0.7446     0.7446     0.7733     2         
56  BZD-intermediate    BZD-short  0.8517 0.6030     0.6030     0.6380     2         
60           doxepin      placebo  0.0121 0.1567     0.1567     0.2609     2         
61           doxepin      placebo -0.1937 0.1406     0.1406     0.2516     2         
70         melatonin      placebo -0.8426 0.3300     0.3300     0.3904     2         
71          BZD-long    BZD-short -0.1276 0.5779     0.5779     0.6144     2         
75           placebo    ramelteon  0.2925 0.0947     0.0947     0.2291     2         
77       eszopiclone      placebo -0.6157 0.1283     0.1283     0.2449     2         
80           placebo     zolpidem  0.7344 0.5965     0.5965     0.6319     2         
81           placebo     zolpidem  1.1386 0.6224     0.6224     0.6564     2         
99      daridorexant     zolpidem  0.2238 0.1582     0.1820     0.3137     3        *
99           placebo     zolpidem  0.5154 0.1841     0.2630     0.3571     3        *
99      daridorexant      placebo -0.2916 0.1585     0.1824     0.3140     3        *
106      eszopiclone    zopiclone -0.3361 0.1428     0.1428     0.2528     2         
111 BZD-intermediate      placebo -0.2163 0.3340     0.4128     0.4854     3        *
111 BZD-intermediate trimipramine  0.0832 0.3290     0.4005     0.4751     3        *
111          placebo trimipramine  0.2995 0.3302     0.4032     0.4774     3        *
112          placebo     zolpidem  1.0894 0.2248     0.2248     0.3067     2         
114          placebo     zolpidem  0.3111 0.1427     0.1427     0.2528     2         
118 BZD-intermediate    BZD-short  0.1121 0.3566     0.3566     0.4132     2         
119          placebo     zolpidem  0.6942 0.3071     0.3071     0.3712     2         
133        BZD-short     zaleplon  0.6136 0.2205     0.2576     0.3639     3        *
133          placebo     zaleplon  0.2980 0.2114     0.2417     0.3506     3        *
133        BZD-short      placebo  0.3156 0.2491     0.3513     0.4243     3        *
134          placebo     zaleplon  0.2057 0.2037     0.2037     0.2916     2         
137          placebo     zolpidem  0.2478 0.1424     0.1424     0.2526     2         
139          placebo    ramelteon  0.3833 0.1541     0.1541     0.2594     2         
140        BZD-short     zolpidem  0.2262 0.2510     0.3111     0.4026     3        *
140          placebo     zolpidem -0.2586 0.2415     0.2888     0.3853     3        *
140        BZD-short      placebo  0.4848 0.2512     0.3116     0.4030     3        *
142 BZD-intermediate      placebo -1.5800 0.3929     0.3929     0.4448     2         
144      eszopiclone      placebo -0.3036 0.1259     0.1259     0.2437     2         
145          placebo    ramelteon  0.3221 0.1226     0.1226     0.2420     2         
151          placebo     zaleplon  0.0910 0.2464     0.3011     0.3950     3        *
151         zaleplon     zolpidem -0.3322 0.2455     0.2990     0.3933     3        *
151          placebo     zolpidem -0.2412 0.2487     0.3069     0.3993     3        *
152          placebo     zaleplon  0.0908 0.2373     0.2373     0.3160     2         
153      lemborexant     zolpidem -0.4978 0.0778     0.0877     0.2693     3        *
153          placebo     zolpidem -0.0428 0.0949     0.1372     0.2855     3        *
153      lemborexant      placebo -0.4550 0.0838     0.0978     0.2744     3        *
154      lemborexant      placebo -0.8324 0.1868     0.1868     0.2800     2         
158          placebo  seltorexant  0.2886 0.1391     0.1555     0.2992     3        *
158          placebo     zolpidem  0.1203 0.1703     0.2697     0.3493     3        *
158      seltorexant     zolpidem -0.1683 0.1388     0.1551     0.2989     3        *
159     daridorexant      placebo -0.3134 0.0699     0.0699     0.2201     2         
160     daridorexant      placebo -0.1758 0.0807     0.0807     0.2237     2         

Number of treatment arms (by study):
    narms
10      2
12      2
22      2
45      2
46      2
47      2
51      3
52      2
54      2
55      2
56      2
60      2
61      2
70      2
71      2
75      2
77      2
80      2
81      2
99      3
106     2
111     3
112     2
114     2
118     2
119     2
133     3
134     2
137     2
139     2
140     3
142     2
144     2
145     2
151     3
152     2
153     3
154     2
158     3
159     2
160     2

Results (fixed effects model):

              treat1       treat2     SMD             95%-CI     Q leverage
10           placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  0.17     0.19
12       eszopiclone      placebo -0.4690 [-0.6405; -0.2975]  0.16     0.03
22          BZD-long      placebo -0.1271 [-0.4429;  0.1886]  1.53     0.24
45           placebo   suvorexant  0.2554 [ 0.1160;  0.3947]  0.10     0.55
46           placebo   suvorexant  0.2554 [ 0.1160;  0.3947]  0.12     0.45
47           placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  0.14     0.01
51          BZD-long      placebo -0.1271 [-0.4429;  0.1886]  0.04        .
51         BZD-short      placebo  0.1694 [-0.0761;  0.4149]  0.05        .
51          BZD-long    BZD-short -0.2966 [-0.6278;  0.0347]  0.26        .
52          BZD-long    zopiclone  0.0195 [-0.4145;  0.4534]  0.18     0.12
54  BZD-intermediate     BZD-long -0.0009 [-0.4616;  0.4599]  6.76     0.12
55          BZD-long    BZD-short -0.2966 [-0.6278;  0.0347]  7.27     0.05
56  BZD-intermediate    BZD-short -0.2974 [-0.6946;  0.0998]  3.63     0.11
60           doxepin      placebo -0.1019 [-0.3070;  0.1032]  0.53     0.45
61           doxepin      placebo -0.1019 [-0.3070;  0.1032]  0.43     0.55
70         melatonin      placebo -0.8426 [-1.4893; -0.1959]  0.00     1.00
71          BZD-long    BZD-short -0.2966 [-0.6278;  0.0347]  0.09     0.09
75           placebo    ramelteon  0.3188 [ 0.1868;  0.4509]  0.08     0.51
77       eszopiclone      placebo -0.4690 [-0.6405; -0.2975]  1.31     0.47
80           placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  0.78     0.01
81           placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  2.23     0.01
99      daridorexant     zolpidem -0.0293 [-0.1571;  0.0986]  1.93        .
99           placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  1.36        .
99      daridorexant      placebo -0.2376 [-0.3336; -0.1415]  0.09        .
106      eszopiclone    zopiclone -0.3224 [-0.5960; -0.0488]  0.01     0.96
111 BZD-intermediate      placebo -0.1280 [-0.5110;  0.2550]  0.05        .
111 BZD-intermediate trimipramine  0.1270 [-0.4615;  0.7155]  0.01        .
111          placebo trimipramine  0.2550 [-0.3343;  0.8444]  0.01        .
112          placebo     zolpidem  0.2083 [ 0.1171;  0.2995] 15.37     0.04
114          placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  0.52     0.11
118 BZD-intermediate    BZD-short -0.2974 [-0.6946;  0.0998]  1.32     0.32
119          placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  2.50     0.02
133        BZD-short     zaleplon  0.4334 [ 0.1460;  0.7208]  0.49        .
133          placebo     zaleplon  0.2640 [ 0.0602;  0.4679]  0.02        .
133        BZD-short      placebo  0.1694 [-0.0761;  0.4149]  0.17        .
134          placebo     zaleplon  0.2640 [ 0.0602;  0.4679]  0.08     0.26
137          placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  0.08     0.11
139          placebo    ramelteon  0.3188 [ 0.1868;  0.4509]  0.17     0.19
140        BZD-short     zolpidem  0.3777 [ 0.1219;  0.6336]  0.24        .
140          placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  2.61        .
140        BZD-short      placebo  0.1694 [-0.0761;  0.4149]  1.02        .
142 BZD-intermediate      placebo -0.1280 [-0.5110;  0.2550] 13.66     0.25
144      eszopiclone      placebo -0.4690 [-0.6405; -0.2975]  1.73     0.48
145          placebo    ramelteon  0.3188 [ 0.1868;  0.4509]  0.00     0.30
151          placebo     zaleplon  0.2640 [ 0.0602;  0.4679]  0.33        .
151         zaleplon     zolpidem -0.0557 [-0.2735;  0.1621]  0.85        .
151          placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  2.15        .
152          placebo     zaleplon  0.2640 [ 0.0602;  0.4679]  0.53     0.19
153      lemborexant     zolpidem -0.4119 [-0.5412; -0.2825]  0.96        .
153          placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  3.35        .
153      lemborexant      placebo -0.6202 [-0.7491; -0.4912]  2.85        .
154      lemborexant      placebo -0.6202 [-0.7491; -0.4912]  1.29     0.12
158          placebo  seltorexant  0.3328 [ 0.1127;  0.5528]  0.08        .
158          placebo     zolpidem  0.2083 [ 0.1171;  0.2995]  0.11        .
158      seltorexant     zolpidem -0.1244 [-0.3444;  0.0956]  0.08        .
159     daridorexant      placebo -0.2376 [-0.3336; -0.1415]  1.18     0.49
160     daridorexant      placebo -0.2376 [-0.3336; -0.1415]  0.59     0.37

Results (random effects model):

              treat1       treat2     SMD             95%-CI
10           placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
12       eszopiclone      placebo -0.4966 [-0.8101; -0.1830]
22          BZD-long      placebo -0.2037 [-0.5950;  0.1876]
45           placebo   suvorexant  0.2526 [-0.0687;  0.5738]
46           placebo   suvorexant  0.2526 [-0.0687;  0.5738]
47           placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
51          BZD-long      placebo -0.2037 [-0.5950;  0.1876]
51         BZD-short      placebo  0.1348 [-0.1754;  0.4451]
51          BZD-long    BZD-short -0.3386 [-0.7487;  0.0716]
52          BZD-long    zopiclone -0.0015 [-0.6306;  0.6276]
54  BZD-intermediate     BZD-long  0.0925 [-0.4449;  0.6300]
55          BZD-long    BZD-short -0.3386 [-0.7487;  0.0716]
56  BZD-intermediate    BZD-short -0.2460 [-0.7041;  0.2121]
60           doxepin      placebo -0.0945 [-0.4495;  0.2604]
61           doxepin      placebo -0.0945 [-0.4495;  0.2604]
70         melatonin      placebo -0.8426 [-1.6078; -0.0775]
71          BZD-long    BZD-short -0.3386 [-0.7487;  0.0716]
75           placebo    ramelteon  0.3289 [ 0.0544;  0.6033]
77       eszopiclone      placebo -0.4966 [-0.8101; -0.1830]
80           placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
81           placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
99      daridorexant     zolpidem  0.0522 [-0.2318;  0.3362]
99           placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
99      daridorexant      placebo -0.2206 [-0.4731;  0.0319]
106      eszopiclone    zopiclone -0.2944 [-0.7619;  0.1732]
111 BZD-intermediate      placebo -0.1112 [-0.5521;  0.3297]
111 BZD-intermediate trimipramine  0.1355 [-0.5600;  0.8310]
111          placebo trimipramine  0.2467 [-0.4495;  0.9428]
112          placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
114          placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
118 BZD-intermediate    BZD-short -0.2460 [-0.7041;  0.2121]
119          placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
133        BZD-short     zaleplon  0.4102 [ 0.0291;  0.7914]
133          placebo     zaleplon  0.2754 [-0.0058;  0.5566]
133        BZD-short      placebo  0.1348 [-0.1754;  0.4451]
134          placebo     zaleplon  0.2754 [-0.0058;  0.5566]
137          placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
139          placebo    ramelteon  0.3289 [ 0.0544;  0.6033]
140        BZD-short     zolpidem  0.4077 [ 0.0721;  0.7432]
140          placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
140        BZD-short      placebo  0.1348 [-0.1754;  0.4451]
142 BZD-intermediate      placebo -0.1112 [-0.5521;  0.3297]
144      eszopiclone      placebo -0.4966 [-0.8101; -0.1830]
145          placebo    ramelteon  0.3289 [ 0.0544;  0.6033]
151          placebo     zaleplon  0.2754 [-0.0058;  0.5566]
151         zaleplon     zolpidem -0.0026 [-0.3133;  0.3082]
151          placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
152          placebo     zaleplon  0.2754 [-0.0058;  0.5566]
153      lemborexant     zolpidem -0.4123 [-0.7399; -0.0847]
153          placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
153      lemborexant      placebo -0.6851 [-1.0006; -0.3697]
154      lemborexant      placebo -0.6851 [-1.0006; -0.3697]
158          placebo  seltorexant  0.3650 [-0.0571;  0.7870]
158          placebo     zolpidem  0.2728 [ 0.1135;  0.4322]
158      seltorexant     zolpidem -0.0922 [-0.5142;  0.3298]
159     daridorexant      placebo -0.2206 [-0.4731;  0.0319]
160     daridorexant      placebo -0.2206 [-0.4731;  0.0319]

Number of studies: k = 41
Number of pairwise comparisons: m = 57
Number of observations: o = 7938
Number of treatments: n = 16
Number of designs: d = 24

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value
BZD-intermediate -0.1280 [-0.5110;  0.2550] -0.65   0.5125
BZD-long         -0.1271 [-0.4429;  0.1886] -0.79   0.4299
BZD-short         0.1694 [-0.0761;  0.4149]  1.35   0.1763
daridorexant     -0.2376 [-0.3336; -0.1415] -4.85 < 0.0001
doxepin          -0.1019 [-0.3070;  0.1032] -0.97   0.3303
eszopiclone      -0.4690 [-0.6405; -0.2975] -5.36 < 0.0001
lemborexant      -0.6202 [-0.7491; -0.4912] -9.43 < 0.0001
melatonin        -0.8426 [-1.4893; -0.1959] -2.55   0.0107
placebo                .                  .     .        .
ramelteon        -0.3188 [-0.4509; -0.1868] -4.73 < 0.0001
seltorexant      -0.3328 [-0.5528; -0.1127] -2.96   0.0030
suvorexant       -0.2554 [-0.3947; -0.1160] -3.59   0.0003
trimipramine     -0.2550 [-0.8444;  0.3343] -0.85   0.3964
zaleplon         -0.2640 [-0.4679; -0.0602] -2.54   0.0111
zolpidem         -0.2083 [-0.2995; -0.1171] -4.48 < 0.0001
zopiclone        -0.1466 [-0.4654;  0.1722] -0.90   0.3675

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value             95%-PI
BZD-intermediate -0.1112 [-0.5521;  0.3297] -0.49   0.6211 [-0.7354;  0.5130]
BZD-long         -0.2037 [-0.5950;  0.1876] -1.02   0.3075 [-0.7912;  0.3838]
BZD-short         0.1348 [-0.1754;  0.4451]  0.85   0.3943 [-0.3980;  0.6676]
daridorexant     -0.2206 [-0.4731;  0.0319] -1.71   0.0868 [-0.7195;  0.2783]
doxepin          -0.0945 [-0.4495;  0.2604] -0.52   0.6017 [-0.6566;  0.4676]
eszopiclone      -0.4966 [-0.8101; -0.1830] -3.10   0.0019 [-1.0315;  0.0383]
lemborexant      -0.6851 [-1.0006; -0.3697] -4.26 < 0.0001 [-1.2212; -0.1490]
melatonin        -0.8426 [-1.6078; -0.0775] -2.16   0.0309 [-1.7432;  0.0579]
placebo                .                  .     .        .                  .
ramelteon        -0.3289 [-0.6033; -0.0544] -2.35   0.0188 [-0.8401;  0.1824]
seltorexant      -0.3650 [-0.7870;  0.0571] -1.70   0.0901 [-0.9750;  0.2450]
suvorexant       -0.2526 [-0.5738;  0.0687] -1.54   0.1233 [-0.7924;  0.2872]
trimipramine     -0.2467 [-0.9428;  0.4495] -0.69   0.4874 [-1.0848;  0.5914]
zaleplon         -0.2754 [-0.5566;  0.0058] -1.92   0.0549 [-0.7905;  0.2398]
zolpidem         -0.2728 [-0.4322; -0.1135] -3.36   0.0008 [-0.7284;  0.1828]
zopiclone        -0.2022 [-0.7447;  0.3402] -0.73   0.4650 [-0.9074;  0.5029]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.0435; tau = 0.2086; I^2 = 59.3% [41.1%; 72.0%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                    Q d.f.  p-value
Total           83.64   34 < 0.0001
Within designs  30.52   17   0.0228
Between designs 53.11   17 < 0.0001
[1] "A total of 16 treatments are included in the network."
[1] "A total of 41 studies are included in this analysis."
[1] "A total of 7938 participants are included in this analysis."
[1] "The following studies were included in this analysis: 10 12 22 45 46 47 51 52 54 55 56 60 61 70 71 75 77 80 81 99 106 111 112 114 118 119 133 134 137 139 140 142 144 145 151 152 153 154 158 159 160"
[1] "Estimated heterogeneity tau-squared0.04"
[1] "Global test for inconsistency, p-value 0.00001 (Q=53, d.o.f. 17)"
[1] "File created on 2022-06-01"
